CY1109257T1 - Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων - Google Patents

Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων

Info

Publication number
CY1109257T1
CY1109257T1 CY20091100595T CY091100595T CY1109257T1 CY 1109257 T1 CY1109257 T1 CY 1109257T1 CY 20091100595 T CY20091100595 T CY 20091100595T CY 091100595 T CY091100595 T CY 091100595T CY 1109257 T1 CY1109257 T1 CY 1109257T1
Authority
CY
Cyprus
Prior art keywords
peptide
dna sequence
polypeptide
juv
similar
Prior art date
Application number
CY20091100595T
Other languages
Greek (el)
English (en)
Inventor
Arvind Devshi Varsani
Edward Peter Rybicki
Original Assignee
University Of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Of Cape Town filed Critical University Of Cape Town
Publication of CY1109257T1 publication Critical patent/CY1109257T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20091100595T 2002-05-17 2009-06-04 Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων CY1109257T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200203957 2002-05-17
EP03727750A EP1506222B2 (en) 2002-05-17 2003-05-19 Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide, virus-like particles prepared therefrom and a method for preparing the particles

Publications (1)

Publication Number Publication Date
CY1109257T1 true CY1109257T1 (el) 2014-07-02

Family

ID=29550639

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100595T CY1109257T1 (el) 2002-05-17 2009-06-04 Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων

Country Status (13)

Country Link
US (2) US7407807B2 (enExample)
EP (1) EP1506222B2 (enExample)
JP (2) JP4614765B2 (enExample)
AT (1) ATE424409T1 (enExample)
AU (1) AU2003232951B2 (enExample)
CA (1) CA2486450C (enExample)
CY (1) CY1109257T1 (enExample)
DE (1) DE60326449D1 (enExample)
DK (1) DK1506222T3 (enExample)
ES (1) ES2323634T5 (enExample)
PT (1) PT1506222E (enExample)
SI (1) SI1506222T1 (enExample)
WO (1) WO2003097673A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
WO2006119516A2 (en) 2005-04-29 2006-11-09 University Of Cape Town Expression of viral proteins in plants
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
WO2009055491A2 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
PE20120563A1 (es) 2009-06-25 2012-05-17 Glaxosmithkline Biolog Sa Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
EP2576840B1 (en) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
KR102013801B1 (ko) 2011-12-01 2019-08-23 유니버시티 오브 케이프 타운 Ｈｐｖ 키메라 입자
WO2015009853A1 (en) * 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6228368B1 (en) † 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19812941A1 (de) † 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor
US6926897B1 (en) † 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
ATE344052T1 (de) * 1998-08-14 2006-11-15 Merck & Co Inc Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
GB9921146D0 (en) † 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CN102458440A (zh) † 2009-04-10 2012-05-16 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)

Also Published As

Publication number Publication date
PT1506222E (pt) 2009-06-12
JP4614765B2 (ja) 2011-01-19
CA2486450C (en) 2013-11-19
WO2003097673A3 (en) 2004-03-18
ATE424409T1 (de) 2009-03-15
EP1506222B2 (en) 2012-05-23
US8163557B2 (en) 2012-04-24
WO2003097673A2 (en) 2003-11-27
US20060035319A1 (en) 2006-02-16
JP2010263899A (ja) 2010-11-25
EP1506222B1 (en) 2009-03-04
ES2323634T3 (es) 2009-07-22
US7407807B2 (en) 2008-08-05
CA2486450A1 (en) 2003-11-27
AU2003232951B2 (en) 2009-07-23
JP2006507797A (ja) 2006-03-09
DK1506222T3 (da) 2009-07-06
WO2003097673B1 (en) 2004-04-22
DE60326449D1 (de) 2009-04-16
SI1506222T1 (sl) 2009-10-31
ES2323634T5 (es) 2012-09-04
EP1506222A2 (en) 2005-02-16
AU2003232951A1 (en) 2003-12-02
US20090047302A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY1109257T1 (el) Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων
MXPA05005051A (es) Vacuna de vector adenoviral.
DK1618888T3 (da) Fremstilling af humant papillomvirus-capsidprotein og viruslignende partikler
MXPA03009354A (es) Un clon infeccioso de adnc del virus del sindrome reproductivo y respiratorio porcino (prrs) norteamericano y sus usos.
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
ATE327259T1 (de) Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
DE69535018D1 (de) Papillomavirus vakzine
ATE369428T1 (de) Behandlung von gebärmutterhalskrebs
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
WO2002081709A3 (en) Modified hpv e6 and e7 genes and proteins useful for vaccination
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
TW200509964A (en) VP1 of foot-and-mouth disease virus
HUP0304053A2 (hu) Új expressziós vektorok és azok alkalmazása
CO5580837A2 (es) Vacuna dna que codifica al menos dos proteinas tempranas no estructurales de papilomavirus
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
SE0002498D0 (sv) Papillomavirus vaccine
WO2005062871A3 (en) Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
FR2859221B1 (fr) Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations